Design Therapeutics, Inc. DSGN
10.80 USD +0.59 (+5.78%)
At closeNov 9, 2026, 4:01 PM EST
10.80 0.00 0.00%
After hours · Nov 9, 4:01 PM ET
10.10 Day range 10.83
6.68 52-week range 17.25
- YTD
- +15.14%
- 1 year
- +42.86%
News
benzinga.com RBC Capital Maintains Outperform on Design Therapeutics, Lowers Price Target to $19 RBC Capital analyst Leonid Timashev maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform and lowers the price target from $20 to $19.
benzinga.com Design Therapeutics Q3 EPS $(0.32) Beats $(0.35) Estimate Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.35) by 8.57 percent. This is a 6.67 percent decrease over losses of…
globenewswire.com Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates DT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027 Cash and securities of $208.6 million at quarter-end provide strong financial runway…
benzinga.com Wells Fargo Initiates Coverage On Design Therapeutics with Overweight Rating, Announces Price Target of $26 Wells Fargo analyst Tianqi Hang initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Overweight rating and announces Price Target of $26.
benzinga.com Marvell Technology, PayPal, Rubrik And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures mostly lower, Nasdaq 100 down 0.3%. Marvell Technology shares fall 7.6% after beating estimates, other stocks also drop in pre-market.
benzinga.com Design Therapeutics Q2 EPS $(0.32) Beats $(0.34) Estimate Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 5.88 percent increase over losses of…- benzinga.com Design Therapeutics Starts Patient Dosing In Its Phase 1 Multiple-Ascending Dose Clinical Study Of DT-818 In Adults With Myotonic Dystrophy Type-1 Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the initiation of patient dosing in…
benzinga.com TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other big gainers include IMVT, SLS, TE, VUZI, ROIV, POET, ARM, AMC, ALAB, DSGN, and TLN.
benzinga.com Design Therapeutics Stock Wobbles After Rare Genetic Disease Data Design Therapeutics reported Phase 1/2 data for DT-216P2, showing biomarker and clinical improvements in Friedreich ataxia patients.
benzinga.com Crude Oil Gains Over 2%; US Homebuilder Sentiment Increases In May Dow falls over 100 points, NASDAQ down 1.20% and S&P 500 down 0.64%. Energy shares surge, tech stocks drop. NAHB/Wells Fargo Housing Market Index up to 37.
benzinga.com Nasdaq Down 200 Points; Brady Earnings Top Views US stocks lower as Nasdaq falls 200 points, Dow down 0.04% and S&P 500 down 0.37%. Energy shares up 1.8%, tech stocks down 1.6%. Brady Corp reports strong earnings. Sunshine Biopharma, Virax Biolabs,…
benzinga.com Design Therapeutics Announces Biomarker And Clinical Data From Its Ongoing Phase 1/2 RESTORE-FA Trial Evaluating DT-216P2 In Patients With Friedreich Ataxia; Patients Demonstrated Improvements In The Modified Friedreich's Ataxia Rating Scale And In The Upright Stability Score Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced positive biomarker and clinical data…
benzinga.com Jim Cramer: Design Therapeutics Is 'Pure Spec,' Buy This Health Care Stock Cramer likes Silicon Motion, whose shares fell 2.2% to settle at $263.85 on Thursday. Wynn shares declined 0.8% to close at $95.43.
benzinga.com Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures down 0.1%, Dole PLC drops 5.9% after missing earning estimates, other stocks also decline in pre-market trading.
benzinga.com Oppenheimer Maintains Outperform on Design Therapeutics, Raises Price Target to $21 Oppenheimer analyst Kostas Biliouris maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform and raises the price target from $18 to $21.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com Design Therapeutics Q1 EPS $(0.29) Beats $(0.34) Estimate Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.34) by 14.71 percent. This is a 6.45 percent increase over losses of…
- benzinga.com Jefferies Initiates Coverage On Design Therapeutics with Buy Rating, Announces Price Target of $15 Jefferies analyst Faisal Khurshid initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Buy rating and announces Price Target of $15.
- benzinga.com RBC Capital Maintains Outperform on Design Therapeutics, Raises Price Target to $14 RBC Capital analyst Leonid Timashev maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform and raises the price target from $13 to $14.
- benzinga.com Design Therapeutics Q4 EPS $(0.27) Beats $(0.35) Estimate Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.35) by 23.3 percent. This is a 12.5 percent decrease over losses of…
benzinga.com Oppenheimer Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $18 Oppenheimer analyst Trevor Allred initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Outperform rating and announces Price Target of $18.- benzinga.com Leerink Partners Upgrades Design Therapeutics to Outperform, Raises Price Target to $14 Leerink Partners analyst Joseph Schwartz upgrades Design Therapeutics (NASDAQ:DSGN) from Market Perform to Outperform and raises the price target from $7 to $14.
benzinga.com Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday - benzinga.com RBC Capital Upgrades Design Therapeutics to Outperform, Raises Price Target to $13 RBC Capital analyst Leonid Timashev upgrades Design Therapeutics (NASDAQ:DSGN) from Sector Perform to Outperform and raises the price target from $6 to $13.
- benzinga.com RBC Capital Maintains Sector Perform on Design Therapeutics, Raises Price Target to $6 RBC Capital analyst Leonid Timashev maintains Design Therapeutics (NASDAQ:DSGN) with a Sector Perform and raises the price target from $5 to $6.
benzinga.com Design Therapeutics Q3 EPS $(0.30) Beats $(0.34) Estimate Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.34) by 11.76 percent. This is a 30.43 percent decrease over losses of…- benzinga.com Design Therapeutics Gets Clearance To Start Dosing DM1 Participants In Phase 1 Multiple-Ascending Dose Study Of DT-818 In Australia In H1 2026 Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced progress and updated milestones…
benzinga.com Steven Cohen's Biotech Bets Are Getting Bolder — And Smaller Billionaire hedge fund manager Steven Cohen is diving into small-cap biotech with new stakes in two clinical-stage companies, signaling confidence in their potential for outsized returns.- benzinga.com Design Therapeutics Q2 EPS $(0.34) Misses $(0.33) Estimate Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.33) by 3.03 percent. This is a 61.9 percent decrease over losses of…
- benzinga.com Design Therapeutics Submitted An Investigational New Drug Application For DT-216P2 With The FDA, The Company Received A Clinical Hold Notice On The IND Application From FDA Noting Nonclinical Deficiencies Further details will be provided in an official letter from FDA within 30 days and the company plans to address their questions, once received.IND Application Submitted to Expand RESTORE-FA Trial to…
- benzinga.com Design Therapeutics Announced That The First Friedreich Ataxia Patient Has Been Dosed Via Intravenous Infusion In Its RESTORE-FA Open-label Phase 1/2 Multiple-ascending Dose Trial Of Dt-216P2, Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Demonstrated Favorable Safety and Pharmacokinetics The RESTORE-FA trial is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of IV and subcutaneous administration of DT-216P2 in patients with FA. DT-216P2…
benzinga.com Design Therapeutics Q1 EPS $(0.31) Misses $(0.28) Estimate Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.28) by 10.71 percent. This is a 55 percent decrease over losses of…- benzinga.com 'FDA Names Vinay Prasad as New Head of Vaccines, Biologics'- Bloomberg Law https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics
benzinga.com Design Therapeutics Releases Phase 1 Data For DT-168 Supporting Advancement Into Phase 2 Biomarker Trial For Patients With Fuchs Endothelial Corneal Dystrophy esign Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced favorable data from a Phase 1 single-…- benzinga.com Design Therapeutics To Present Update On Progress Of DT-168 Program For FECD At Eyecelerator At Park City 2025 On May 2, 2025 CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,…
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Design Therapeutics Q4 2024 GAAP EPS $(0.24) Beats $(0.28) Estimate Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.28) by 14.29 percent. This is a 14.29 percent decrease over losses of…
benzinga.com Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket 
benzinga.com Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- benzinga.com Why Cemtrex Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
- benzinga.com MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday.
- benzinga.com Lamb Weston Posts Weak Q2 Results, Joins Micron, Lennar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- benzinga.com Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
- benzinga.com Design Therapeutics Q3 2024 GAAP EPS $(0.23) Beats $(0.31) Estimate Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.31) by 25.81 percent.
- benzinga.com RBC Capital Reiterates Sector Perform on Design Therapeutics, Maintains $4 Price Target RBC Capital analyst Leonid Timashev reiterates Design Therapeutics (NASDAQ:DSGN) with a Sector Perform and maintains $4 price target.